Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non Operating Income: 2020-2024

Historic Non Operating Income for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $5.0 million.

  • Tarsus Pharmaceuticals' Non Operating Income rose 11.60% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 1.26%. This contributed to the annual value of $5.0 million for FY2024, which is 30.97% down from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Non Operating Income stood at $5.0 million, which was down 30.97% from $7.3 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Non Operating Income registered a high of $7.3 million during FY2023, and its lowest value of -$1.6 million during FY2021.
  • In the last 3 years, Tarsus Pharmaceuticals' Non Operating Income had a median value of $5.0 million in 2024 and averaged $4.3 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Non Operating Income slumped by 959.04% in 2021, and later spiked by 1,077.47% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Non Operating Income (Yearly) stood at $188,000 in 2020, then slumped by 959.04% to -$1.6 million in 2021, then spiked by 138.20% to $617,000 in 2022, then soared by 1,077.47% to $7.3 million in 2023, then slumped by 30.97% to $5.0 million in 2024.